Fractyl Health, Inc. is set to unveil new preclinical data on its Rejuva Smart GLP-1 pancreatic gene therapy platform at the upcoming American Diabetes Association's 85th Scientific Sessions, scheduled for June 20-23, 2025, in Chicago, Illinois.

During the Late Breaking Poster Session on June 22, 2025, from 12:30 p.m. to 1:30 p.m., the company will present an abstract titled 'Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice'.

The poster presentation will be numbered 1970-LB and will be available on Fractyl's website following the conference.

Fractyl Health aims to transition from merely managing symptoms of metabolic diseases to offering durable, disease-modifying therapies that tackle the root causes of these conditions.

The company is committed to developing innovative treatments for metabolic diseases, particularly obesity and type 2 diabetes, which are on the rise globally despite the availability of existing therapies.

The Rejuva platform employs advanced delivery systems designed to specifically target the pancreas, although it has not yet undergone regulatory evaluation for investigational or commercial use.

Based in Burlington, Massachusetts, Fractyl Health focuses on pioneering adeno-associated virus (AAV)-based gene therapies that are currently in the preclinical development stage.